A leading bio-pharma company, amid significant capital crunch, sought an insights-driven strategy to develop its lead compound into a new drug
WNS leveraged its rich domain and analytical expertise to power the bio-pharma company’s commercial and clinical assessment of its lead compound
The bio-pharma company could efficiently leverage its capital to action the most viable clinical and commercial indications
Drug discovery and development is an expensive and protracted process. Identifying a lead compound and successfully using it to develop a new drug is hugely complex, and spread over several years and lengthy clinical cycles. Multiple factors such as market size and competitors’ pipelines have to be considered. As drug development costs and timelines spiral and success rates decline, companies need to transform the overall process – using levers such as analytics to generate smart insights and improve decision-making.
To develop its lead compound into a new drug (for cancer treatment) amid significant crunch in capital. The right insights were required to cost-effectively execute the clinical development of this lead compound, while aligning with the commercial opportunity. This involved expediting the approval from Food and Drug Administration (FDA) and improving cash flow to further invest in the lead compound as well as develop other compounds in the Research and Development (R&D) pipeline.
WNS leveraged its domain and analytical expertise to support the bio-pharma company in the commercial and clinical assessment of the lead compound. Key aspects of the solution included:
Creation of a three-dimensional framework to prioritize indications for the lead compound based on commercial and clinical attractiveness, and ease of development
Preparation of various in-depth business case studies to showcase the revenue potential of the lead compound
Development of forecasting models for multiple scenarios related to competitors’ pipelines and potential pricing of the lead compound to account for the uncertainty and sensitivity parameters
The forecasting models and business cases were continually updated to ensure that revenue predictions of all indications reflected more real-time scenarios.
The bio-pharma company could successfully position the medical and revenue potential of its lead compound to internal and external stakeholders. Key benefits include:
Efficient utilization of capital in planning and executing the most clinically and commercially viable indications
Streamlined strategy for executing the drug development plan
Improved scope of validating internal thinking with independent external assessments to enable registration-directed study and multiple Proof of Concept (PoC) studies with respect to the lead compound
Join the conversation
24 December 2020
16 October 2019
01 March 2022